DATE: July 1, 2020
TIME: 10:00am PT
Moving forward to the 2035 global END TB targets, access to accurate TB and DR-TB diagnostic tools are needed more than ever before. As a direct consequence of COVID-19, an additional 6.3 million new TB cases and 1.4 million deaths are estimated between 2020 and 2025, and high-burden countries will remain on top. There is a strong need to enhance the capacity for accurate diagnosis of TB and DR-TB as people ill with COVID-19 and TB show similar symptoms. Major progress has been made for rapid and accurate diagnosis of TB and DR-TB using real-time, molecular assays and this could harness TB case findings in the COVID-19 outbreak.
This webinar intends to exchange views on the role and contributions of polyvalent, high throughput molecular platforms in early case finding and prompt treatment of TB and DR-TB. It consists of three areas of focus: the current diagnostic algorithm for TB and DR-TB in high-burden countries; the need for laboratory capacity for DR-TB and impact on population; and the power of polyvalent diagnostic platforms to address TB and DR-TB case findings in the COVID-19 outbreak.
Learning Objectives:
Understand current testing and platform challenges of MTB and RIF/INH
Understand the clinical utility of mTB and RIF/INH resistance testing in managing mTB patients
Understand the workflow process to implement mTB testing in areas that need scale up and automation
Webinars will be available for unlimited on-demand viewing after live event.
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.
Forgot your password?
Reset it here.
Don't have an account? Sign up for FREE.